Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
46.08
73.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Relative Value
The Relative Value of one
ROVI
stock under the Base Case scenario is
67.77
EUR.
Compared to the current market price of 73.6 EUR,
Laboratorios Farmaceuticos ROVI SA
is
Overvalued by 8%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
ROVI Competitors Multiples
Laboratorios Farmaceuticos ROVI SA Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ES |
|
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
|
3.8B EUR | 5.2 | 31 | 20.1 | 23.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD | 17.3 | 56 | 37.5 | 40.2 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 5.8 | -157.8 | 0.4 | 1.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
528.3B USD | 5.7 | 21 | 17.2 | 22.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
275.5B CHF | 4.5 | 29.2 | 12.4 | 14.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP | 0 | 0.3 | 0 | 0 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.8B CHF | 5 | 19.4 | 15.3 | 19.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
271.4B USD | 4.2 | 14.3 | 10.1 | 12 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK | 5.6 | 17 | 11.8 | 13.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
148.1B USD | 2.4 | 15.1 | 7.6 | 10.4 |
